Table 1.

Demographic and baseline characteristics of the patients (intention-to-treat sample)

	Indoprocaf tbs (n = 72)	Indoprocaf effe (n = 71)	Indoprocaf total (n = 143)	Sumatriptan (n = 138)	Total (n = 281)
Sex (n, %)
Male	10 (14)	20 (28)	30 (21)	31 (22)	61 (22)
Female	62 (86)	51 (72)	113 (79)	107 (78)	220 (78)
Age (years)
Mean	35	34	34	36	35
Range	20–60	19–58	19–60	18–64	18–64
Migraine diagnosis (n, %)
Migraine without aura	67 (93)	64 (90)	131 (92)	129 (93)	260 (92)
Migraine with aura	1 (1)	5 (7)	6 (4)	4 (3)	10 (4)
Migraine with and without aura	4 (6)	2 (3)	6 (4)	5 (4)	11 (4)
MIDAS grade (n, %)
I	3 (4)	11 (16)	14 (10)	14 (10)	28 (10)
II	8 (11)	10 (14)	18 (13)	18 (13)	36 (13)
III	25 (35)	23 (32)	48 (33)	48 (35)	96 (34)
IV	36 (50)	27 (38)	63 (44)	58 (42)	121 (43)

Indoprocaf indicates indomethacin, prochlorperazine and caffeine; tbs, coated tablets; effe, effervescent tablets.